Abstract：OBJECTIVE To develop a method for determination of the dissolution of inhaled drugs by using indacaterol maleate, ipratropium bromide and budesonide as model drugs, and explore the law of dissolution of inhaled drugs. METHODS Samples were prepared and the improved paddle apparatus method (USP dissolution assay-fifth method) was used for dissolution experiment. Samples were taken at a certain time, and the drug concentration was determined by HPLC. The sample dispersion method, dissolution medium and membrane were optimized, meanwhile inhaled drugs with different properties were measured and dissolution curve was modeled. RESULTS An improved paddle apparatus method for simulating drug dissolution in respiratory tract was developed, samples were collected using the new generation impactor and the dissolution parameters were determined to be as follows: 150 mL of dissolution medium (250 mL dissolution cup), 2% Tween 80-PBS dissolution medium, 4.5 cm watch glass (4.7 cm drug-loaded membranes and 4.7 cm mesh screen), glass microfiber filters, double-layer membranes, drug-loaded membrane fixation method (level the mesh screen) and sampling time of 3 h; Weibull model was suitable for fitting the three drugs with different solubility (r2>0.999 1). CONCLUSION The method is simple and reproducible, and can be used to determine the dissolution of inhalation drugs; the dissolution process of inhaled drugs is consistent with Weibull model.
HASTEDT J E, BÄCKMAN P, CLARK A R, et al. Erratum to: scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD[J]. Aaps Open, 2016,2:1. 10.1186/S41120-016-0005-2.
[2]
GRAY V A, HICKEY A J, BALMER P, et al. The inhalation ad hoc advisory panel for the USP performance tests of inhalation dosage forms[J]. Pharmacopeial Forum, 2008, 34(4):1068-1074.
[3]
DAS S C, STEWART P J. The influence of lung surfactant liquid crystalline nanostructures on respiratory drug delivery[J]. Int J Pharm, 2016, 514(2):465-474.
[4]
MARQUES M R C, LOEBENBERG R, ALMUKAINZI M. Simulated biological fluids with possible application in dissolution testing[J]. Diss Technol, 2011, 18(3):15-28.
[5]
ONOUE S, AOKI Y, KAWABATA Y, et al. Development of inhalable nanocrystalline solid dispersion of Tranilast for airway inflammatory diseases[J]. J Pharm Sci, 2011, 100(2):622-633.
[6]
SATO H, OGAWA K, KOIO Y, et al. Development of cyclosporine A-loaded dry-emulsion formulation using highly purified glycerol monooleate for safe inhalation therapy[J]. Int J Pharm, 2013, 448(1):282-289.
[7]
ALFREDO G A. A European perspective on orally inhaled products: in vitro requirements for a biowaiver[J]. J Aerosol Med Pulm Drug Deliv, 2014, 27(6):419-429.
[8]
GRAINGER C I, SAUNDERS M, BUTTINI F, et al. Critical characteristics for corticosteroid solution metered dose inhaler bioequivalence[J]. Mol Pharm, 2012, 9(3):563-569.
[9]
SON Y J, HORNG M, COPLEY M, et al. Optimization of an in vitro dissolution test method for inhalation formulations[J]. Diss Technol, 2010, 17(2):6-14.
[10]
MAY S, JENSEN B, WOLKENHAUER M, et al. Dissolution techniques for in vitro testing of dry powders for inhalation[J]. Pharm Res, 2012, 29(8):2157-2166.
[11]
SON Y J, MCCONVILLE J T. Development of a standardized dissolution test method for inhaled pharmaceutical formulations[J]. Inter J Pharm, 2009, 382(1):15-22.
[12]
PAI R V, JAIN R R, BANNALIKAR A S, et al. Development and evaluation of chitosan microparticles based dry powder inhalation formulations of rifampicin and rifabutin[J]. J Aerosol Med Pulm Drug Deliv, 2016, 29(2):179-195.
[13]
SALAMA R O, TRAINI D, CHAN H K, et al. Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols[J]. Eur J Pharm Biopharm Eur J Pharm Biopharm Official J Arbeitsgemeinschaft Für Pharm Verfahrenstechnik E V, 2008, 70(1):145-152.
[14]
JASPART S, BERTHOLET P, PIEL G, et al. Solid lipid microparticles as a sustained release system for pulmonary drug delivery[J]. Eur J Pharm Biopharm, 2007, 65(1):47-56.
[15]
ARORA D, SHAH K A, HALQUIST M S, et al. In vitro, aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products[J]. Pharm Res, 2010, 27(5):786-795.
[16]
Ch. P(2015) Vol Ⅳ (中国药典2015年版.四部) [S]. 2015: 326.
[17]
CHAN J G, CHAN H K, PRESTIDGE C A, et al. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics[J]. Eur J Pharm Biopharm Official J Arbeitsgemeinschaft Fur Pharm Verfahrenstechnik E V, 2013, 83(2):285-292.
[18]
ROHRSCHNEIDER M, BHAGWAT S, KRAMPE R, et al. Evaluation of the transwell system for characterization of dissolution behavior of inhalation drugs: effects of membrane and surfactant[J]. Mol Pharm, 2015, 12(8):2618-2624.
2019, Vol. 54 
